Last reviewed · How we verify
Shenzhen SiBiono GeneTech Co.,Ltd — Portfolio Competitive Intelligence Brief
5 marketed
0 filed
0 Phase 3
6 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| chemotherapy plus p53 | chemotherapy plus p53 | marketed | Combination chemotherapy with p53 gene therapy | p53 tumor suppressor protein | Oncology | |
| p53 gene with surgery | p53 gene with surgery | marketed | Gene therapy (p53 tumor suppressor) | p53 (tumor protein p53) | Oncology | |
| rAd-p53 gene | rAd-p53 gene | marketed | Gene therapy; oncolytic virus | p53 tumor suppressor gene | Oncology | |
| p53 with chemotherapy | p53 with chemotherapy | marketed | Gene therapy; recombinant adenovirus vector | p53 (tumor suppressor protein) | Oncology | |
| p53 gene therapy | p53 gene therapy | marketed | Gene therapy | p53 (tumor suppressor protein) | Oncology |
Therapeutic area mix
- Oncology · 5
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abeona Therapeutics, Inc · 1 shared drug class
- AskBio Inc · 1 shared drug class
- BioLab 612 LLC · 1 shared drug class
- Brain Neurotherapy Bio, Inc. · 1 shared drug class
- Emily de los Reyes · 1 shared drug class
- Eva Morava-Kozicz · 1 shared drug class
- Kolon TissueGene, Inc. · 1 shared drug class
- 4D Molecular Therapeutics · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shenzhen SiBiono GeneTech Co.,Ltd:
- Shenzhen SiBiono GeneTech Co.,Ltd pipeline updates — RSS
- Shenzhen SiBiono GeneTech Co.,Ltd pipeline updates — Atom
- Shenzhen SiBiono GeneTech Co.,Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shenzhen SiBiono GeneTech Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shenzhen-sibiono-genetech-co-ltd. Accessed 2026-05-16.